A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma

Video

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.

Case: A 74-Year-Old Man with Diffuse Large B-Cell Lymphoma

Initial Presentation

  • A 74-year-old man presented with fever, 14-lb unintentional weight loss and occasional chest pain
  • PMH: DM, medically controlled
  • PE: tired-appearing man; palpable bilateral cervical lymphadenopathy

Clinical Work-up

  • Labs: LDH 2 times above normal; Hb 10.8 g/dL; bilirubin 2.3 mg/dL; creatinine 1.7 mg/fl; all others WNL
  • Hepatitis B, C and HIV negative
  • Lymph node biopsy; CD 20+ confirmed DLBCL; IHC panel: CD 10+, CD 19+
  • Imaging:
    • Whole body PET/CT scan showed activity the cervical lymph node region, largest node 2.5 cm; evidence of axillary and thoracic subcutaneous tissue involvement
  • Ann Arbor stage 4; IPI: high-risk; ECOG PS 1

Treatment

  • Treatment initiated with R-CHOP + RT; well-tolerated
    • Interim PET scan after 4 cycles; progressive diseases noted
  • Due to transplant ineligibility patient was treated with tafasitamab + lenalidomide
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

Targeted Oncology Staff
March 6th 2025
Article

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary refractory or early relapsed DBLCL since the introduction of CAR T-cell therapy.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

Nichole Tucker
June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

Zamto-Cel Shows Durable Responses in Relapsed/Refractory DLBCL

Zamto-Cel Shows Durable Responses in Relapsed/Refractory DLBCL

Chris Ryan
February 14th 2025
Article

Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

Read More

Yared Considers Referral and Bridging Decisions for Early Relapse in DLBCL

Yared Considers Referral and Bridging Decisions for Early Relapse in DLBCL

Targeted Oncology Staff
January 16th 2025
Article

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a patient with early relapsed diffuse large B-cell lymphoma.

Read More

Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL

Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL

Silas Inman
Published: December 8th 2024 | Updated: December 8th 2024
Article

The addition of zilovertamab vedotin to R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) resulted in a 100% complete response rate in patients with previously untreated DLBCL.

Read More

LAG-3/PD-L1 Bispecific Shows Response After CAR T in DLBCL

LAG-3/PD-L1 Bispecific Shows Response After CAR T in DLBCL

Gina Mauro
December 8th 2024
Article

A LAG-3/PD-L1 bispecific antibody, FS188, showed a modest objective response rate in a small cohort of patients with relapsed/refractory diffuse large B-cell lymphoma.

Read More